METHOD FOR DETECTING METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) STRAINS

• US 20110269138A1
• Filed: 12/29/2009
• Published: 11/03/2011
• Est. Priority Date: 12/30/2008
• Status: Abandoned Application

• Current Assignee: Qiagen Hamburg GmbH (Qiagen NV)
• Original Assignee: Qiagen Hamburg GmbH (Qiagen NV)
• Inventors: Wiezer, Arnim
• Application Number:
  US13/143,050
• Publication Number:
  US 20110269138A1
• Time in Patent Office: Days
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: C12Q 2537/149 Sequential reactions

Abstract

The present invention relates, inter alia, to a method for detecting methicillin-resistant Staphylococcus aureus (MRSA) strains, wherein one of the following method variants is carried out:

• • variant A
  • a) chromosomal DNA of S. aureus is isolated from the sample by means of a genome probe, and
  • b) a nucleotide sequence which is specific for MRSA is detected in the isolated DNA;
  • or
  • variant B
  • a) DNA is isolated from the sample, wherein the isolation makes use of a genome probe which is specific for an MRSA nucleotide sequence, preferably an MRSA resistance gene, and
  • b) the DNA isolated in step a) is tested for specific sequences of S. aureus.

In addition, suitable kits for carrying out the corresponding methods are provided.

Claims

1. A method for detecting MRSA in a sample, comprising:

per variant A,

a) isolating chromosomal DNA of S. aureus from the sample using a genome probe, and

b) determining the presence or absence of a nucleotide sequence specific for MRSA in the chromosomal DNA isolated in step a), wherein the presence of the nucleotide sequence indicates the presence of MRSA in the sample;

or

per variant B,

a) isolating DNA from the sample using a genome probe specific for an MRSA nucleotide sequence, and

b) determining the presence or absence of a specific sequence of S. aureus in the DNA isolated in step a) wherein the presence of the specific sequence of S. aureus indicates the presence of MRSA in the sample.

2. The method according to claim 1, wherein when per variant A, the genome probe is complementary to a segment of the chromosomal DNA, which segment is specific for S. aureus.

3. The method according to claim 1, wherein when per variant A,

a) the genome probe is complementary to a segment of the chromosomal S. aureus DNA in the vicinity of the SCCmec insertion site;

b) the genome probe is complementary to a segment of the chromosomal S. aureus DNA within a region of 25 kb to the SCCmec insertion site;

c) the genome probe is complementary to a segment of the chromosomal S. aureus DNA that is in the vicinity of the mecA gene and is S. aureus-specific;

d) the genome probe is complementary to a segment of the chromosomal S. aureus DNA that is within a region of 25 kb of the mecA gene and is S. aureus-specific; and

/or

e) the genome probe comprises a sequence as set forth in SEQ ID NO;

7 or is a genome probe which is complementary to a segment of the chromosomal S. aureus DNA within 1 kb of the region of the S. aureus chromosome to which the sequence having SEQ ID NO;

7 is complementary.

4. The method according to claim 1, wherein

a) the genome probe is ≧

20 nucleotides in length;

b) the genome probe is bound to a support;

c) the genome probe is bound to the support via a spacer;

d) the genome probe is present covalently bonded to a support;

e) the genome probe is contacted with the DNA in a first step and the support is added in a second step;

f) the genome probe is present bound to the support before it is contacted with the DNA; and

/or

g) when per variant A, multiple different genome probes are used to isolate the chromosomal DNA of S. aureus, or when per variant B, a mixture of genome probes are used to isolate the DNA.

5. The method according to claim 1, wherein when per variant A, the nucleotide sequence is a resistance gene.

6. The method according to claim 1, wherein when per variant A, the presence or absence of the nucleotide sequence specific for MRSA is determined by means of PCR;

or wherein when per variant B, the presence or absence of the specific sequence of S. aureus in the DNA isolated in step a) is determined by means of PCR.

7. The method according to claim 1, wherein when per variant B, the presence or absence of multiple different specific sequences of S. aureus in the DNA isolated in step a) is determined.

8. The method according to claim 1, wherein DNA is isolated from the sample in a preceding step

(i) before the chromosomal S. aureus DNA is isolated using the genome probe in step a) when per variant A, or

(ii) before the DNA is isolated by means of the genome probe specific for an MRSA nucleotide sequence in step a) when per variant B.

9. The method according to claim 1, wherein the sample is a mixed sample.

10. The method according to claim 1, further comprising determining the presence or absence of the Panton-Valentine leukocidin (PVL) gene.

11. The method according to claim 1, further comprising detecting the presence or absence of a control DNA specific for a human sequence.

12. A kit for detecting MRSA in a sample, comprising:

per variant A,

a) at least one genome probe suitable for isolating DNA of S. aureus, and

b) means for detecting a nucleotide sequence specific for MRSA;

or

per variant B,

a) at least one genome probe suitable for isolating from a sample DNA comprising an MRSA resistance gene, and

b) means for detecting an S. aureus-specific DNA sequences.

13. The kit according to claim 12, wherein per variant A,

a) the kit comprises a genome probe, complementary to a segment of the chromosomal S. aureus DNA, which segment is specific for S. aureus;

b) the kit comprises a genome probe complementary to a segment of the chromosomal S. aureus DNA in the vicinity of the SCCmec insertion site;

c) the kit comprises a genome probe complementary to a region within 20 kb of the SCCmec insertion site;

d) the kit comprises a genome probe containing the sequence having SEQ ID NO;

7 or has a genome probe that binds within 1 kb of the region of S. aureus to which the sequence having SEQ ID NO;

7 is complementary;

e) the kit comprises means for the PCR detection of the nucleotide sequence specific for MRSA; and

/or

f) the kit comprises means for PCR detection of mecA, at least one primer comprising a sequence selected from the sequences having SEQ ID NOS;

9 to 11.

14. The kit according to claim 12, wherein when per variant B, the kit comprises:

a) means for detecting multiple different specific sequences of S. aureus; and

/or

b) means for PCR detection of the S. aureus-specific sequences.

15. The kit according to claim 12, wherein

a) the kit comprises a genome probe that is ≧

20 nucleotides;

b) the kit comprises multiple different genome probes;

c) the kit comprises a support for binding the genome probe or the genome probe is present bound to the support; and

/or

d) the kit comprises oligonucleotides or oligonucleotide mimetics for detecting the specific sequences.